ATE349467T1 - Amyloid beta protein (globularer aufbau und seine verwendung) - Google Patents

Amyloid beta protein (globularer aufbau und seine verwendung)

Info

Publication number
ATE349467T1
ATE349467T1 AT98905006T AT98905006T ATE349467T1 AT E349467 T1 ATE349467 T1 AT E349467T1 AT 98905006 T AT98905006 T AT 98905006T AT 98905006 T AT98905006 T AT 98905006T AT E349467 T1 ATE349467 T1 AT E349467T1
Authority
AT
Austria
Prior art keywords
addls
activity
formation
amyloid beta
compounds
Prior art date
Application number
AT98905006T
Other languages
English (en)
Inventor
Grant A Krafft
William L Klein
Brett A Chromy
Mary P Lambert
Caleb E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Original Assignee
Univ Northwestern
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Univ Southern California filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE349467T1 publication Critical patent/ATE349467T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98905006T 1997-02-05 1998-02-05 Amyloid beta protein (globularer aufbau und seine verwendung) ATE349467T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/796,089 US6218506B1 (en) 1997-02-05 1997-02-05 Amyloid β protein (globular assembly and uses thereof)

Publications (1)

Publication Number Publication Date
ATE349467T1 true ATE349467T1 (de) 2007-01-15

Family

ID=25167266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98905006T ATE349467T1 (de) 1997-02-05 1998-02-05 Amyloid beta protein (globularer aufbau und seine verwendung)

Country Status (12)

Country Link
US (2) US6218506B1 (de)
EP (2) EP0998495B1 (de)
JP (2) JP3512815B2 (de)
AT (1) ATE349467T1 (de)
AU (1) AU735825B2 (de)
BR (1) BR9807185A (de)
CA (1) CA2279555C (de)
DE (1) DE69836740T2 (de)
DK (1) DK0998495T3 (de)
ES (1) ES2280090T3 (de)
PT (1) PT998495E (de)
WO (1) WO1998033815A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU5602100A (en) 1999-06-09 2000-12-28 Arch Development Corporation Recombinant prion-like genes and proteins and materials and methods comprising same
ATE283285T1 (de) 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CO5271708A1 (es) 1999-12-23 2003-04-30 Upjohn Co Ensayo y metodos basados en el uso de canales de sodio como objetivos de amiloide b o de sus agregados
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
EP1944040B1 (de) * 2001-08-17 2012-08-01 Washington University Assay-Verfahren für Alzheimer
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006508072A (ja) * 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
JP2008500286A (ja) * 2004-05-14 2008-01-10 ノースウエスタン ユニバーシティ Ａｄｄｌ受容体を含む組成物、関連する組成物、および関連する方法
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006047254A1 (en) * 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (de) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US8420093B2 (en) 2005-02-14 2013-04-16 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
US7731962B2 (en) * 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
TW200700432A (en) * 2005-03-05 2007-01-01 Abbott Gmbh & Co Kg Screening method, process for purifying of non-diffusible a β oligomers, selective antibodies against said non-diffusible a β oligomers and a process for manufacturing of said antibodies
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US20090258824A1 (en) * 2005-07-29 2009-10-15 Ashe Karen H Amyloid beta receptor and uses thereof
US20080014596A1 (en) * 2005-11-16 2008-01-17 Jasna Jerecic ADDL Binding to Hippocampal Neurons
JP2009518010A (ja) 2005-11-30 2009-05-07 アボット・ラボラトリーズ ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP4876224B2 (ja) * 2006-06-05 2012-02-15 財団法人ヒューマンサイエンス振興財団 アミロイドβオリゴマー並びにその製造方法及び使用方法
RU2498999C2 (ru) * 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
ES2323725T3 (es) * 2006-07-28 2009-07-23 Vista Ventures Gmbh Procedimiento para la deteccion de oligomeros de amiloide beta en fluidos corporales.
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) * 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9006283B2 (en) * 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
WO2009008890A1 (en) 2007-07-12 2009-01-15 Acumen Pharmaceuticals, Inc. METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
US8993714B2 (en) * 2007-10-26 2015-03-31 Imiplex Llc Streptavidin macromolecular adaptor and complexes thereof
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US9285363B2 (en) 2009-05-11 2016-03-15 Imiplex Llc Method of protein nanostructure fabrication
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CN102596997B (zh) * 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2463369A4 (de) 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd Humanisierter antikörper gegen amyloid-b-oligomere
MX2012001708A (es) 2009-08-07 2012-05-22 Kyowa Hakko Kirin Co Ltd Anticuerpo humanizado anti-oligomero de amiloide b.
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US20130115227A1 (en) 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN103782171B (zh) 2011-07-13 2016-12-14 默沙东公司 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
EP4597103A1 (de) * 2022-09-27 2025-08-06 Kaneka Corporation Verfahren zur beurteilung der gerinnungshemmungsaktivität oder gerinnungsförderungsaktivität gegen koagulatives protein
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010569A1 (en) 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)

Also Published As

Publication number Publication date
DK0998495T3 (da) 2007-05-07
AU6273598A (en) 1998-08-25
CA2279555C (en) 2012-05-01
DE69836740T2 (de) 2007-10-11
WO1998033815A1 (en) 1998-08-06
US6218506B1 (en) 2001-04-17
US7638283B2 (en) 2009-12-29
US20060166275A1 (en) 2006-07-27
PT998495E (pt) 2007-03-30
EP1808444A1 (de) 2007-07-18
EP0998495B1 (de) 2006-12-27
AU735825B2 (en) 2001-07-19
CA2279555A1 (en) 1998-08-06
ES2280090T3 (es) 2007-09-01
BR9807185A (pt) 2000-01-25
DE69836740D1 (de) 2007-02-08
JP3512815B2 (ja) 2004-03-31
JP2004091492A (ja) 2004-03-25
EP0998495A1 (de) 2000-05-10
JP2001501972A (ja) 2001-02-13

Similar Documents

Publication Publication Date Title
DE69836740D1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
ATE283285T1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
DE69635740D1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69434540D1 (de) Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
NO976094L (no) Nye peptider avledet av humant varmesjokkprotein 60 for behandling av diabetes, fremgangsmåte og sett
DE68925004D1 (de) Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
PL346246A1 (en) Modulating multiple lineage kinase proteins
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
DE68909465D1 (de) Behandlung von pferdeviehbestand.
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE68909304D1 (de) Aminosäuren für der Behandung neurodegenerativer Störungen.
DE69502380D1 (de) 4-aminoderivate von 5-substituierten mycophenolsäuren
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
DE3888715D1 (de) Reg-Gen und dadurch kodiertes Protein.
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
ATE95036T1 (de) Behandlung von pferdeviehbestand.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0998495

Country of ref document: EP

REN Ceased due to non-payment of the annual fee